Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s ...

Some of the soundbite health care policy proposals that candidates bring up for short-term political impact could in practice ...

Itovebi — also known as inavolisib — is designed to be given with drugs from Pfizer Inc. and AstraZeneca plc to treat adults ...

Jasper Therapeutics, a biotech looking to make stem cell transplants less taxing and to treat immune-mediated diseases, ...

Swiss drug makers Lonza and Roche agreed in March to the sale the Vacaville campus in the heart of Solano County’s burgeoning ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline one-year results from ...

Lonza Group AG / Key word (s): Quarter Results Q3 2024 Qualitative Update: Lonza Confirms Full-Year Outlook 2024 24-Oct-2024 / 07:00 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR ...

Genentech, a member of the Roche (RHHBY), announced topline one-year results from the open-label, single-arm Phase IV ...

Data from the Rainbowfish trial was presented at the World Muscle Society (WMS) Congress 2024 in Prague, Czech Republic.

The Food and Drug Administration (FDA) approved Genentech's Itovebi (inavolisib), in combination with palbociclib (Ibrance) ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...